JP2025505261A5 - - Google Patents
Info
- Publication number
- JP2025505261A5 JP2025505261A5 JP2024547680A JP2024547680A JP2025505261A5 JP 2025505261 A5 JP2025505261 A5 JP 2025505261A5 JP 2024547680 A JP2024547680 A JP 2024547680A JP 2024547680 A JP2024547680 A JP 2024547680A JP 2025505261 A5 JP2025505261 A5 JP 2025505261A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- lorperidone
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309874P | 2022-02-14 | 2022-02-14 | |
| US63/309,874 | 2022-02-14 | ||
| PCT/US2023/062500 WO2023154927A1 (en) | 2022-02-14 | 2023-02-13 | Use of roluperidone in preventing relapse in schizophrenia patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025505261A JP2025505261A (ja) | 2025-02-21 |
| JP2025505261A5 true JP2025505261A5 (https=) | 2026-02-20 |
Family
ID=85569991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547680A Pending JP2025505261A (ja) | 2022-02-14 | 2023-02-13 | 統合失調症患者における再発の予防におけるロルペリドンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230255953A1 (https=) |
| EP (2) | EP4479049B1 (https=) |
| JP (1) | JP2025505261A (https=) |
| KR (1) | KR20240161650A (https=) |
| CN (1) | CN118984705A (https=) |
| AU (1) | AU2023217097A1 (https=) |
| CA (1) | CA3243767A1 (https=) |
| CL (1) | CL2024002418A1 (https=) |
| ES (1) | ES3064313T3 (https=) |
| IL (1) | IL314859A (https=) |
| MX (1) | MX2024009828A (https=) |
| WO (1) | WO2023154927A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| WO2020264486A1 (en) * | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
-
2023
- 2023-02-13 EP EP23710619.0A patent/EP4479049B1/en active Active
- 2023-02-13 JP JP2024547680A patent/JP2025505261A/ja active Pending
- 2023-02-13 AU AU2023217097A patent/AU2023217097A1/en active Pending
- 2023-02-13 US US18/168,028 patent/US20230255953A1/en active Pending
- 2023-02-13 WO PCT/US2023/062500 patent/WO2023154927A1/en not_active Ceased
- 2023-02-13 EP EP25223916.5A patent/EP4729122A2/en active Pending
- 2023-02-13 KR KR1020247031088A patent/KR20240161650A/ko active Pending
- 2023-02-13 IL IL314859A patent/IL314859A/en unknown
- 2023-02-13 CA CA3243767A patent/CA3243767A1/en active Pending
- 2023-02-13 CN CN202380033205.7A patent/CN118984705A/zh active Pending
- 2023-02-13 ES ES23710619T patent/ES3064313T3/es active Active
-
2024
- 2024-08-12 CL CL2024002418A patent/CL2024002418A1/es unknown
- 2024-08-12 MX MX2024009828A patent/MX2024009828A/es unknown